Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma

NCT00112736 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00112736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2005
Completion date
April 30, 2014
Enrollment
69 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

adult anaplastic astrocytoma, adult anaplastic oligodendroglioma, adult diffuse astrocytoma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult mixed glioma, adult pilocytic astrocytoma, adult pineal gland astrocytoma, adult subependymal giant cell astrocytoma, recurrent adult brain tumor